Risk-Guided Screening for Atrial Fibrillation Using Electronic Health Records
Abstract
BACKGROUND: Screening for atrial fibrillation (AF) on the basis of AF risk may be more effective. We aimed to develop, externally validate, and prospectively test a machine learning prediction model using electronic health records (EHRs) to guide AF screening. METHODS: We developed and validated a random forest prediction model for new AF within 6 months, using age, sex, and 10 comorbidities (Future Innovations in Novel Detection of Atrial Fibrillation [FIND-AF] 2.0) in EHRs in the United Kingdom (n=2 081 139), Japan (n=7 795 244), Israel (n=2 166 795), Canada (n=627 919), and China (n=149 145). We conducted a prospective study where participants ≥30 years old without AF and with a CHA 2 DS 2 -VASc score ≥2 in men and ≥3 in women, stratified by FIND-AF 2.0 into high and low risk, undertook 4 ECG recordings per day for 3 weeks using a handheld ECG recorder, with a primary outcome of newly diagnosed AF. We estimated stroke risk associated with nonanticoagulated AF in patients with high FIND-AF 2.0 risk in the FinACAF (Finnish Anticoagulation in Atrial Fibrillation) registry of patients with AF (n=229 565). RESULTS: FIND-AF 2.0 was applicable to all EHRs and showed good to excellent prediction performance (United Kingdom: area under the receiver operating characteristic curve [AUROC], 0.819 [95% CI, 0.809–0.829]; Israel: AUROC, 0.835 [95% CI, 0.828–0.842]; Japan: AUROC, 0.751 [95% CI, 0.745–0.757]; Canada: AUROC, 0.747 [95% CI, 0.741–0.753]; China: AUROC, 0.753 [95% CI, 0.725–0.771]), with AUROC>0.7 in men and women in all cohorts, and improved performance compared with CHA 2 DS 2 -VASc and C 2 HEST. Of 1923 participants from 15 sites in the prospective study (mean age, 70.2 [SD 9.4] years), with a mean of 74.8 (SD, 19.4) ECG recordings, AF was diagnosed in 5 of 902 (0.6%) with low FIND-AF 2.0 risk and 46 of 1021 (4.5%) with high FIND-AF 2.0 risk (odds ratio, 8.46 [95% CI, 3.35–21.40], P <0.001). Median AF burden among high FIND-AF 2.0 risk–detected cases was 33.4% (interquartile range, 5.1%–91.6%), and 96.1% initiated oral anticoagulants. In the FinACAF registry, the rate of ischemic stroke for patients with high FIND-AF 2.0 risk, AF, and no anticoagulants was 6.0 events per 100 patient-years. CONCLUSIONS: The EHR-based machine learning model, FIND-AF 2.0, identifies a high-risk subpopulation for AF diagnosis among patients at elevated risk of stroke and could enable scalable, EHR-driven, risk-guided AF screening.
Article Details
Authors (43)
Ramesh Nadarajah
Jianhua Wu
Ali Wahab
Catherine Reynolds
Mohammad Haris
Tobin Joseph
Keerthenan Raveendra
Ben Hurdus
Khalid Kazi
Sheena Bennett
Chris Hayward
Ben Mercer
Jing Kang
Translational Immunology, Genentech
Chenyi Gao
Wolfson Institute of Population Health, Queen Mary, University of London, London, United Kingdom (J.W., C.G.).
Yoko M. Nakao
Koji Kawakami
Carlin Chang
Department of Medicine, University of Hong Kong, Hong Kong SAR, China. (C.C.)
Abraham Wai
Department of Emergency Medicine, University of Hong Kong, Hong Kong SAR, China. (A.W.)
Jiandong Zhou
Gary Tse
Talish Razi Benita
Community Medical Services Division, Clalit Healthcare Services, Tel Aviv, Israel (T.R.B., R.A., M.H., D.Z.).
Lior Rokach
Ronen Arbel
Community Medical Services Division, Clalit Healthcare Services, Tel Aviv, Israel (T.R.B., R.A., M.H., D.Z.).
Moti Haim
Community Medical Services Division, Clalit Healthcare Services, Tel Aviv, Israel (T.R.B., R.A., M.H., D.Z.).
Doron Zahger
Community Medical Services Division, Clalit Healthcare Services, Tel Aviv, Israel (T.R.B., R.A., M.H., D.Z.).
Dina Labib
Department of Cardiac Sciences and Libin Cardiovascular Institute, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada (D.L., J.F., J.A.W.).
Jacqueline Flewitt
Department of Cardiac Sciences and Libin Cardiovascular Institute, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada (D.L., J.F., J.A.W.).
James A. White
Department of Cardiac Sciences and Libin Cardiovascular Institute, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada (D.L., J.F., J.A.W.).
Konsta Teppo
Heart Center, Turku University Hospital and University of Turku, Turku, Finland. (K.T., K.E.J.A.)
Mika Lehto
Jorvi Hospital, Department of Internal Medicine (M. Lehto), HUS Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
Ville Langén
Division of Medicine, Turku University Hospital and University of Turku, Turku, Finland. (V.L.)
Aleksi K. Winstén
K.E. Juhani Airaksinen
Heart Center, Turku University Hospital and University of Turku, Turku, Finland. (K.T., K.E.J.A.)
Jari Haukka
Department of Public Health, University of Helsinki, Helsinki, Finland (J. Haukka).
Olli Halminen
Departments of Health and Social Management, University of Eastern Finland, Finland. (O.H.)
Jukka Putaala
Department of Neurology, University of Helsinki and Helsinki University Hospital, Helsinki
Juha Hartikainen
Miika Linna
Health and Social Management, University of Eastern Finland, Finland.(M. Linna)
Ben Freedman
Heart Research Institute, Sydney Medical School, Charles Perkins Center, and Cardiology Department, The University of Sydney, Sydney, NSW, Australia (B.F.).
Emma Svennberg
Karolinska Institutet, Department of Medicine, Karolinska University Hospital, Stockholm, Sweden (E.S.).
A. John Camm
Cardiology Clinical Academic Group, Molecular and Clinical Sciences Institute, City St. George’s University of London, London
Gregory Y. H. Lip
Chris P. Gale